Back to top

Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home

Read MoreHide Full Article

Masimo Corporation (MASI - Free Report) received FDA approval for the domestic use of Rad-97 Pulse CO-Oximeter. This product will offer non-invasive and continuous monitoring.

The product comprises Measure-through Motion and Low Perfusion SET pulse oximetry and upgradeable rainbow technologies, in a compact standalone monitor. The device combines advanced connectivity and communication capabilities for telehealth with an interface, which is easily customized for use at home.

Why Rad-97?

Rad-97’s built-in WiFi amenity allows clinicians to remotely observe patient status while facilitating automatic data transfer to hospital electronic medical record (EMC) systems. It can record and store data for up to 96 hours.

The company stated that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users, giving them access to applicable settings and messages. The optional integrated camera allows clinicians to observe patients through live audio and video.

Masimo Corporation Price and Consensus



Lucrative Prospects in Niche Space


The number of patients receiving care at home is increasing. Accordingly, there is a growing need for high-quality home monitoring and telehealth equipments.

Per a research by Lucintel, the global medical device market is expected to reach an estimated $342.9 billion by 2021, at a CAGR of 4.6%. The key factors are multiplying healthcare expenditure, enhanced health awareness among people and ageing population.

The price movement of Masimo Corporation has been unfavorable over the last year. Notably, the stock has gained almost 25.5%, comparing unfavorably with the industry’s rally of roughly 26.5%.



Zacks Ranks & Key Picks

Masimo carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical space are Bio-Rad Laboratories (BIO - Free Report) , Centene Corporation (CNC - Free Report) and Exelixis Inc. (EXEL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank Stocks Here.

Bio-Rad has a projected long-term growth rate of 25%. The stock has rallied 13.4% in the last six months, against the industry’s rally of 7.5%.

Centene has an expected growth rate of 16.4% for 2018. Over the last month, the stock has rallied 6.2%, over the broader industry’s gain of 2.1%.

Exelixis has an impressive expected growth rate of 120% for the first quarter of 2018. Over the last year, the stock has gained 64.6%, surpassing the industry’s mere gain of 1%.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

More from Zacks Analyst Blog

You May Like